Nova Mentis Life Science Corp. (CSE: NOVA)
Canada
· Delayed Price · Currency is CAD | Market Cap | 741.59K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -628.58K |
| Shares Out | 148.32M |
| EPS (ttm) | -0.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 28,110 |
| Open | 0.0050 |
| Previous Close | 0.0050 |
| Day's Range | 0.0050 - 0.0050 |
| 52-Week Range | 0.0050 - 0.0300 |
| Beta | 0.77 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 27, 2024 |
About Nova Mentis Life Science
Nova Mentis Life Science Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing diagnostics and psilocybin-based therapeutics for the treatment of neuroinflammatory disorders, including autism spectrum disorder and fragile X syndrome. The company was formerly known as Liberty Leaf Holdings Ltd. and changed its name to Nova Mentis Life Science Corp. in June 2020. Nova Mentis Life Science Corp. was incorporated in 2004 and is based in Vancouver, Canada. [Read more]
Financial Performance
Financial StatementsNews
Nova Mentis Assigns Intellectual Property
Vancouver, British Columbia--(Newsfile Corp. - August 27, 2024) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company") is pleased to announce it has entered ...
CSE Bulletin: WITHDRAWN - Symbol Change - Inactive Designation - Nova Mentis Life Science Corp. (NOVA)
Toronto, Ontario--(Newsfile Corp. - le 8 août/August 2024) - Bulletin 2024-0809 - Symbol Change - Inactive Designation - Nova Mentis Life Science Corp. (NOVA) has been withdrawn. If you have any quest...
CSE Bulletin: Symbol Change - Inactive Designation - Nova Mentis Life Science Corp. (NOVA)
Toronto, Ontario--(Newsfile Corp. - Le 8 août/August 2024) - The Exchange has determined that Nova Mentis Life Science Corp. (the “Issuer”) has not met the continued listing requirements as set out in...
Nova Mentis Announces Change of Directors
Vancouver, British Columbia--(Newsfile Corp. - February 26, 2024) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company") announces the appointment of Steve L...
Nova Mentis Applauds Government Decision to Create Rare Disease Advisory Group
Vancouver, British Columbia--(Newsfile Corp. - November 3, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global l...
Nova Mentis Announces Participant Screening Underway in Canada's First Psilocybin Clinical Trial for Fragile X Syndrome
Vancouver, British Columbia--(Newsfile Corp. - August 30, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global le...
Nova Mentis to Enter mRNA AI Diagnostics Business
Vancouver, British Columbia--(Newsfile Corp. - April 26, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global lea...
Nova Mentis Begins Recruitment in First-of-its-Kind Health Canada Psilocybin Trial
Vancouver, British Columbia--(Newsfile Corp. - April 18, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global lea...
Nova Mentis Receives Institutional Review Board Approval to Commence Psilocybin Clinical Trial
Vancouver, British Columbia--(Newsfile Corp. - April 11, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global lea...
Nova Mentis Provides Corporate Update and 2023 Outlook
Vancouver, British Columbia--(Newsfile Corp. - April 5, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global lead...
Novel Therapeutic Solutions are Needed as Autism Rates Increase
Vancouver, British Columbia--(Newsfile Corp. - March 29, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global lea...
Nova Mentis Granted Health Canada Section 56 Exemption to Begin Psilocybin Clinical Trial
Vancouver, British Columbia--(Newsfile Corp. - February 14, 2023) - Nova Mentis Life Science Corp.
Nova Mentis Appoints Derek Ivany as Executive Chairman
Vancouver, British Columbia--(Newsfile Corp. - January 18, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global l...
Nova Mentis Receives Health Canada Approval for First-Of-Its-Kind Psilocybin Clinical Trial
The human study will evaluate the Company's proprietary psilocybin drug (NM-1001) in the treatment of Fragile X SyndromeVancouver, British Columbia--(Newsfile Corp. - December 22, 2022) - Nova Mentis ...
Nova Mentis' Psilocybin Preclinical Study Published in International Science Journal
Microdose Treatment Modulates CognitionVancouver, British Columbia--(Newsfile Corp. - December 8, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"...
Nova Submits Phase II A Psilocybin Clinical Trial Application to Health Canada
Microdose Psilocybin Safety and Efficacy Clinical Study in Fragile X SyndromeVancouver, British Columbia--(Newsfile Corp. - November 30, 2022) - Nova Mentis Life Science Corp.
Nova Mentis Enters into Research Contract with KGK Science for Phase II A Clinical Trial
Vancouver, British Columbia--(Newsfile Corp. - November 17, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (OTCQB: NMLSF) (FSE: HN3Q) ("NOVA" or the "Company"), a biotechnology company and global ...
Nova Mentis Psilocybin Microdose Capsule Formulation to be Submitted in Health Canada Phase 2A Clinical Trial Application
Vancouver, British Columbia--(Newsfile Corp. - September 29, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global...
Nova Mentis Completes Production of Psilocybin Microdose Capsules
Company Plans to Submit Clinical Trial Application in CanadaVancouver, British Columbia--(Newsfile Corp. - September 15, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (...
Nova Mentis to Present Promising Psilocybin Microdose Data at 18th NFXF International Fragile X Conference
Vancouver, British Columbia--(Newsfile Corp. - July 11, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global lead...
Nova Mentis to Present at the H.C. Wainwright Mental Health Conference
Vancouver, British Columbia--(Newsfile Corp. - June 22, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global lead...
Nova Mentis Files Patent on Diagnosing, Monitoring and Treating Neurological Diseases with Psychoactive Tryptamine Derivatives
mRNA Diagnostic Index to Measure Drug Treatment ResponseVancouver, British Columbia--(Newsfile Corp. - June 16, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or...
Nova Mentis and University of Central Florida to Develop Saliva Serotonin Assay
Vancouver, British Columbia--(Newsfile Corp. - June 9, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leade...
Nova Mentis Receives Controlled Substances Export Approval From The U.S. DEA For The Company's Proprietary Psilocybin Drug NM 1001
Vancouver, British Columbia--(Newsfile Corp. - June 7, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leade...
Nova Mentis Welcomes Autism Behaviour Analyst to its Science Team
Vancouver, British Columbia--(Newsfile Corp. - May 12, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leade...